Patients with TIL(+) immunogenic/hot tumors develop a polyspecific endogenous neoantigen-specific immune response that becomes unable to control tumor growth mainly because of the different inhibitory mechanisms, including the PD-1/PD-L1 pathway. Here, CD274 is linked to neoplasm.